Crossmark

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

Crossref DOI link: https://doi.org/10.1186/s12885-020-07047-1

Published Online: 2020-06-12

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hirata, Kenro http://orcid.org/0000-0003-4536-7781
Hamamoto, Yasuo

Ando, Masahiko

Imamura, Chiyo K.

Yoshimura, Kenichi

Yamazaki, Kentaro

Hironaka, Shuichi

Muro, Kei
Funding

Funding for this research was provided by:

Taiho Pharmaceutical
License Information

Text and Data Mining valid from 2020-06-12

Version of Record valid from 2020-06-12
More Information

Article History

Received: 27 September 2019

Accepted: 6 June 2020

First Online: 12 June 2020

Ethics approval and consent to participate

: The current study has been approved by the Certified Review Board of Keio (CRB3180017), and permission for conducting the study has been obtained from the managements of all participating facilities. Written informed consent for participation will be obtained from participants. Separate written informed consent will be obtained for the assessment of RAM pharmacokinetics and correlative research.

: Not applicable.

: Yasuo Hamamoto is an Associate Editor of this journal. The other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below